International journal of clinical practice
-
Int. J. Clin. Pract. · Jan 2023
Serum Hsa_circ_0005962 Is A Prognostic Biomarker of Paclitaxel Resistance in Nonsmall Cell Lung Cancer Treatment.
Tumor progression and the therapeutic resistance associated with cancer agents are thought to be modulated by circular RNAs (circRNAs); however, its mechanism associated with nonsmall cell lung cancer (NSCLC) is still undetermined. The following investigation aimed to evaluate the involvement of circRNAs with NSCLC. ⋯ The results of this investigation highlight that hsa_circ_0005962 induces chemoresistance in NSCLC patients and, therefore, can act as a physiological target to treat NSCLC.